At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
Dapagliflozin 10mgdrug
Likely dose
Dapagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
In Brief
A Phase 2 clinical trial evaluating Dapagliflozin 10mg for Chronic Kidney Diseases and Proteinuria. Completed, enrolled 53 participants across 7 sites in 3 countries.
Detailed Summary
This study tests the hypothesis that dapagliflozin lowers proteinuria in patients with non-diabetic chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Diseases, Proteinuria
CountriesCanada, Malaysia, Netherlands
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartNov 2017
Primary CompletionNov 2019
Study CompletionDec 2019
TodayJul 2026
First PostedJun 19, 2017
Enrollment StartNov 12, 2017
Primary CompletionNov 1, 2019
Study CompletionDec 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.0 years ago
Interventions
Dapagliflozin 10mgdrug
Tablet